CDK4/6 inhibitor: from quiescence to senescence

CDK4/6 inhibitor: from quiescence to senescence

Bibliographic Details
Main Authors:	Yoshida, Akihiro, Diehl, J. Alan
Format:	Online
Language:	English
Published:	Impact Journals LLC 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675777/

Similar Items

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
by: Kovatcheva, Marta, et al.
Published: (2015)

CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells
by: Laurenti, Elisa, et al.
Published: (2015)

From quiescence to proliferation: Cdk oscillations drive the mammalian cell cycle
by: Gérard, Claude, et al.
Published: (2012)

Hypoxia, MTOR and autophagy: Converging on senescence or quiescence
by: Blagosklonny, Mikhail V.
Published: (2013)

Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin
by: Leontieva, Olga V., et al.
Published: (2011)

CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner
by: Yoshida, Akihiro, et al.
Published: (2013)

Depletion of γ-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation
by: Matsumura, Kengo, et al.
Published: (2016)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
by: Hanxiao Xu, et al.
Published: (2017-04-01)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
by: Lu, Janice
Published: (2015)

Unexpected Outcomes of CDK4/6 Inhibition
by: Choi, Yoon Jong, et al.
Published: (2013)

CDK4/6 inhibition in luminal breast cancer
by: Gampenrieder, Simon Peter, et al.
Published: (2016)

FASCAPLYSIN as a Specific Inhibitor for CDK4: Insights from Molecular Modelling
by: Shafiq, Muhammad Imtiaz, et al.
Published: (2012)

Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
by: Yuan Sun, Ying-xia Li, Hai-jun Wu, Si-hung Wu, Y. Alan Wang, Dian-zhong Luo, D. Joshua Liao
Published: (2011-01-01)

MicroRNA-191 triggers keratinocytes senescence by SATB1 and CDK6 downregulation
by: Lena, A.M., et al.
Published: (2012)

Development of CDK inhibitors as cancer therapeutics
by: Lane, D
Published: (2005)

RB Maintains Quiescence and Prevents Premature Senescence through Upregulation of DNMT1 in Mesenchymal Stromal Cells
by: Lin, Shih-Pei, et al.
Published: (2014)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
by: Chen, Zhenghu, et al.
Published: (2016)

Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence
by: Brookes, Sharon, et al.
Published: (2015)

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion
by: Leontieva, Olga V, et al.
Published: (2013)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
by: Kang, Jian, et al.
Published: (2014)

Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization
by: Mahale, S, et al.
Published: (2015)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
by: Schröder, Lisette B. W., et al.
Published: (2015)

Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors
by: O’Sullivan, Ciara C
Published: (2015)

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
by: Lee, Michael S., et al.
Published: (2016)

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
by: Franco, Jorge, et al.
Published: (2014)

Regulation of CDK4
by: Bockstaele, Laurence, et al.
Published: (2006)

The default state of the cell: Quiescence or proliferation?
by: Parr, Edward
Published: (2012)

A New Description of Cellular Quiescence
by: Coller, Hilary A, et al.
Published: (2006)

Proliferation/quiescence: the controversial "aller-retour"
by: Daignan-Fornier, Bertrand, et al.
Published: (2011)

H4K20 methylation regulates quiescence and chromatin compaction
by: Evertts, Adam G., et al.
Published: (2013)

Identification and Characterization of an Irreversible Inhibitor of CDK2
by: Anscombe, Elizabeth, et al.
Published: (2015)

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
by: Rihani, Ali, et al.
Published: (2015)

CDK6 and p16INK4A in lymphoid malignancies
by: Kollmann, Karoline, et al.
Published: (2013)

p18 inhibits reprogramming through inactivation of Cdk4/6
by: Zhu, Shaohua, et al.
Published: (2016)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
by: Berthet, Cyril, et al.
Published: (2006)

Highlights of the Latest Advances in Research on CDK Inhibitors
by: Cicenas, Jonas, et al.
Published: (2014)

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
by: Ku, Bo Mi, et al.
Published: (2016)

Megakaryocytes regulate hematopoietic stem cell quiescence via Cxcl4 secretion
by: Bruns, Ingmar, et al.
Published: (2014)

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA
by: Perez, Marco, et al.
Published: (2015)

Primary cilia in myoblasts: a role in quiescence
by: Venugopal, N, et al.
Published: (2015)